Asker Healthcare Group (ASKER.ST) Stock Analysis & AI Equity Report

Medical - Care Facilities SEK Explore free reports

Asker Healthcare Group (ASKER.ST) overview

Asker Healthcare Group (ASKER.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Asker Healthcare Group reported revenue of SEK 16,787m and operating profit of SEK 1,009m; the year-end share price was 84.40 SEK and market capitalisation was SEK 31,080m. Asker Healthcare Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Asker Healthcare Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 6,555mFY 2025
Share price84.40 SEKFY 2025 year end
RevenueSEK 16,787mFY 2025
Operating profitSEK 1,009mFY 2025
Net earningsSEK 510mFY 2025
Market capitalisationSEK 31,080mFY 2025 year end

Figures updated on 2026-07-18. Data will be refreshed during report generation.

About Asker Healthcare Group

Asker Healthcare Group is a European healthcare group providing medical products and solutions to caregivers and patients. It operates a network of more than 50 companies across 19 countries, serving healthcare providers through medical supplies, devices and equipment. Growth is driven by organic expansion and acquisitions.

Generate the Asker Healthcare Group report

Asker Healthcare Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Asker Healthcare Group and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.